Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-Center, Open-Label Phase II Clinical Study of Sacituzumab Tirumotecan Combined With Immune Checkpoint Inhibitors for the Later-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT07686588 is registered in ClinicalTrials.gov with Biying Chen as lead sponsor.

NCT NCT07686588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07686588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-Center, Open-Label Phase II Clinical Study of Sacituzumab Tirumotecan Combined With Immune Checkpoint Inhibitors for the Later-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Lead sponsor
Biying Chen
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 1, 2026
Completion date
December 31, 2028
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic head and neck carcinoma